Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, announces that preclinical data demonstrating that BGB324 has potential application as a novel treatment for Chronic Myeloid Leukemia (CML), was presented in a poster at the Annual Meeting of the American Society of Hematology (ASH), which took place on December 7-10, 2013.

The results suggest that BGB324 may be effective as monotherapy in treating patients with drug-resistant CML as a result of exposure to Abelson kinase (Abl) inhibitors such as imatinib, nilotinib and dasatinib, (Novartis's Gleevec and Tasigna, and Bristol Myer Squibb's Sprycel) which are widely used as first line therapy in patients. Long term therapy with these agents can result in the development of resistance and new mutations. Overexpression of the Axl tyrosine kinase is known to confer resistance to treatment with imatinib. Treatment with Abl inhibitors whilst successful in eradicating malignant cells from the blood does not kill the leukemic stem cells which remain active in the bone marrow necessitating life-long treatment with these agents. In contrast treatment with BGB324 was effective in inducing programmed cell death in CML stem cells located in the marrow. The results also revealed that treatment with BGB324 was effective in treating animals infected with CML cells expressing the T315I mutation of ABL which is resistant to treatment with currently approved drugs. The data further underscores the potential of BGB324 in addressing the spread of leukemias and other resistant cancers whose biology is driven by Axl expression.  

BGB324 is a first-in-class, highly selective small molecule inhibitor of the Axl receptor tyrosine kinase. Preclinical in vivo studies have shown that BGB324 has both single agent activity in leukemia and solid tumors and is very effective in preventing and reversing acquired resistance to existing therapies including cytotoxics, protein kinase inhibitors and other targeted therapies. It is the only selective Axl inhibitor in clinical development having recently completed a phase Ia clinical trial. Phase Ib clinical trials are planned in acute myeloid leukemia and non-small cell lung cancer in 2014.

The poster presented at ASH was based on work conducted by Dr. Sonja Loges' group from the Department of Hematology, Oncology and Bone Marrow Transplantation with Section Pneumology and from the Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf.

Sonja Loges, MD PhD, commented: "There is a significant unmet need for novel therapies that can address drug-induced resistant cancers. The results of the preclinical studies presented in this poster support our belief that BGB324, a selective inhibitor to Axl poised for clinical development in acute myeloid leukemia and non-small cell lung cancer, could also offer a promising potential new treatment option for chronic myeloid leukemia, especially in patients that are resistant to the current standard of care. This data further reinforces our hypothesis that Axl plays a critical role in the emergence of a number of drug resistant hematological and solid cancers."


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Gut health and leukemia: Exploring the crucial connection between diet and microbiota changes